Search - tctmd.com

Displaying 21 - 40 of 399

Sort: Relevancy | Date

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

National Data Point to Soaring TAVI Rates in Patients Under 65

News Conference News NY Valves 2024

National Data Point to Soaring TAVI Rates in Patients Under 65

Michael O'Riordan

June 14, 2024

More Trial Evidence Supports Tenecteplase for Acute Stroke Thrombolysis

News Conference News ESOC 2024

More Trial Evidence Supports Tenecteplase for Acute Stroke Thrombolysis

May 21, 2024

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

News Conference News EuroPCR 2024

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

May 16, 2024

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

News Conference News SCAI 2024

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

May 02, 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

April 12, 2024

Need a Statin for Primary Prevention? There’s an App for That

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

April 07, 2024

Isolated vs Concomitant SAVR Offer Similar 5-Year Outcomes: PARTNER 3

News Conference News STS 2024

Isolated vs Concomitant SAVR Offer Similar 5-Year Outcomes: PARTNER 3

Yael L. Maxwell

February 09, 2024

SAVR After Failed TAVI on the Rise, With High Mortality

News Conference News STS 2024

SAVR After Failed TAVI on the Rise, With High Mortality

Yael L. Maxwell

February 05, 2024

TAVI, SAVR Almost Equally Performed in California Patients Under 60

News Conference News STS 2024

TAVI, SAVR Almost Equally Performed in California Patients Under 60

Yael L. Maxwell

February 01, 2024

For LGBTQ+ Patients With Heart Failure, EMR Details Often Absent

News Conference News AHA 2023

For LGBTQ+ Patients With Heart Failure, EMR Details Often Absent

November 17, 2023

Large Study Affirms Safety of Pulsed-Field Ablation, Reveals Some Rare Complications

News Conference News AHA 2023

Large Study Affirms Safety of Pulsed-Field Ablation, Reveals Some Rare Complications

November 13, 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH: Heart-1

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

November 12, 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

News Conference News TCT 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

Michael O'Riordan

October 26, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.